Adjuvants for peptide-based cancer vaccines
Cancer therapies based on T cells have shown impressive clinical benefit. In particular, immune checkpoint blockade therapies with anti-CTLA-4 and anti-PD-1/PD-L1 are causing dramatic tumor shrinkage and prolonged patient survival in a variety of cancers. However, many patients do not benefit, possi...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2016-09-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/4/1/56.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823864495380889600 |
|---|---|
| author | Willem W Overwijk Hiep Khong |
| author_facet | Willem W Overwijk Hiep Khong |
| author_sort | Willem W Overwijk |
| collection | DOAJ |
| description | Cancer therapies based on T cells have shown impressive clinical benefit. In particular, immune checkpoint blockade therapies with anti-CTLA-4 and anti-PD-1/PD-L1 are causing dramatic tumor shrinkage and prolonged patient survival in a variety of cancers. However, many patients do not benefit, possibly due to insufficient spontaneous T cell reactivity against their tumors and/or lacking immune cell infiltration to tumor site. Such tumor-specific T cell responses could be induced through anti-cancer vaccination; but despite great success in animal models, only a few of many cancer vaccine trials have demonstrated robust clinical benefit. One reason for this difference may be the use of potent, effective vaccine adjuvants in animal models, vs. the use of safe, but very weak, vaccine adjuvants in clinical trials. As vaccine adjuvants dictate the type and magnitude of the T cell response after vaccination, it is critical to understand how they work to design safe, but also effective, cancer vaccines for clinical use. Here we discuss current insights into the mechanism of action and practical application of vaccine adjuvants, with a focus on peptide-based cancer vaccines. |
| format | Article |
| id | doaj-art-2f56a3ab17364c7f976b35404b13316f |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2016-09-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-2f56a3ab17364c7f976b35404b13316f2025-02-09T01:35:15ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262016-09-014110.1186/s40425-016-0160-yAdjuvants for peptide-based cancer vaccinesWillem W Overwijk0Hiep Khong1Nektar Therapeutics, San Francisco, California, USAAff1 grid.240145.60000000122914776Department of Melanoma Medical OncologyUniversity of Texas - MD Anderson Cancer Center South Campus Research Building 1, 1515 Holcombe Blvd 77030 Houston TX USACancer therapies based on T cells have shown impressive clinical benefit. In particular, immune checkpoint blockade therapies with anti-CTLA-4 and anti-PD-1/PD-L1 are causing dramatic tumor shrinkage and prolonged patient survival in a variety of cancers. However, many patients do not benefit, possibly due to insufficient spontaneous T cell reactivity against their tumors and/or lacking immune cell infiltration to tumor site. Such tumor-specific T cell responses could be induced through anti-cancer vaccination; but despite great success in animal models, only a few of many cancer vaccine trials have demonstrated robust clinical benefit. One reason for this difference may be the use of potent, effective vaccine adjuvants in animal models, vs. the use of safe, but very weak, vaccine adjuvants in clinical trials. As vaccine adjuvants dictate the type and magnitude of the T cell response after vaccination, it is critical to understand how they work to design safe, but also effective, cancer vaccines for clinical use. Here we discuss current insights into the mechanism of action and practical application of vaccine adjuvants, with a focus on peptide-based cancer vaccines.https://jitc.bmj.com/content/4/1/56.full |
| spellingShingle | Willem W Overwijk Hiep Khong Adjuvants for peptide-based cancer vaccines Journal for ImmunoTherapy of Cancer |
| title | Adjuvants for peptide-based cancer vaccines |
| title_full | Adjuvants for peptide-based cancer vaccines |
| title_fullStr | Adjuvants for peptide-based cancer vaccines |
| title_full_unstemmed | Adjuvants for peptide-based cancer vaccines |
| title_short | Adjuvants for peptide-based cancer vaccines |
| title_sort | adjuvants for peptide based cancer vaccines |
| url | https://jitc.bmj.com/content/4/1/56.full |
| work_keys_str_mv | AT willemwoverwijk adjuvantsforpeptidebasedcancervaccines AT hiepkhong adjuvantsforpeptidebasedcancervaccines |